• 1
    Terpos E,Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005; 16: 122331.
  • 2
    Ribatti D,Nico B,Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 425766.
  • 3
    Baserga R,Peruzzi F,Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 8737.
  • 4
    Georgii-Hemming P,Wiklund HJ,Ljunggren O,Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 22508.
  • 5
    Nilsson K,Georgii-Hemming P,Spets H,Jernberg-Wiklund H. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro. Curr Top Microbiol Immunol 1999; 246: 32535.
  • 6
    Ferlin M,Noraz N,Hertogh C,Brochier J,Taylor N,Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 62634.
  • 7
    Qiang YW,Kopantzev E,Rudikoff S. Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 413846.
  • 8
    Menu E,Kooijman R,Van Valckenborgh E,Asosingh K,Bakkus M,Van Camp B,Vanderkerken K. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004; 90: 107683.
  • 9
    Abboud SL,Bethel CR,Aron DC. Secretion of insulin-like growth factor I and insulin-like growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest 1991; 88: 4705.
  • 10
    Ueland T. GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 2005; 152: 32732.
  • 11
    Wang Y,Nishida S,Elalieh HZ,Long RK,Halloran BP,Bikle DD. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 2006; 21: 13508.
  • 12
    Girnita A,Girnita L,del Prete F,Bartolazzi A,Larsson O,Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64: 23642.
  • 13
    Menu E,Jernberg-Wiklund H,Stromberg T,De Raeve H,Girnita L,Larsson O,Axelson M,Asosingh K,Nilsson K,Van Camp B,Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006; 107: 65560.
  • 14
    Stromberg T,Ekman S,Girnita L,Dimberg LY,Larsson O,Axelson M,Lennartsson J,Hellman U,Carlson K,Osterborg A,Vanderkerken K,Nilsson K, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107: 66978.
  • 15
    Van Valckenborgh E,De Raeve H,Devy L,Blacher S,Munaut C,Noel A,Van Marck E,Van Riet I,Van Camp B,Vanderkerken K. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002; 86: 796802.
  • 16
    Croucher PI,Shipman CM,Lippitt J,Perry M,Asosingh K,Hijzen A,Brabbs AC,van Beek EJ,Holen I,Skerry TM,Dunstan CR,Russell GR, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 353440.
  • 17
    Menu E,De Leenheer E,De Raeve H,Coulton L,Imanishi T,Miyashita K,Van Valckenborgh E,Van Riet I,Van Camp B,Horuk R,Croucher P,Vanderkerken K. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006; 23: 291300.
  • 18
    Vasilcanu D,Weng W-H,Girnita A,Lui WO,Vasilcanu R,Axelson M,Larsson O,Larsson C,Girnita L. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 2006; 25: 318695.
  • 19
    Wu KD,Zhou L,Burtrum D,Ludwig DL,Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56: 34357.
  • 20
    Catrina S-B,Botusan IR,Rantanen A,Catrina AI,Pyakurel P,Savu O,Axelson M,Biberfeld P,Poellinger L,Brismar K. Hypoxia-inducible factor-1α and hypoxia-inducible factor 2α are expressed in Kaposi sarcoma and modulated by insulin-like growth factor 1. Clin Cancer Res 2006; 12: 450614.
  • 21
    Middleton J,Arnott N,Walsh S,Beresford J. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. Bone 1995; 16: 28793.